| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
WILMINGTON, Del.—AstraZeneca has announced that the U.S. District Court forthe District of Columbia issued an opinion and order in AstraZeneca's lawsuitagainst the U.S. Food and Drug Administration (FDA) regarding final marketingapproval of generic quetiapine.
 
The Court denied the company's request for apreliminary injunction and dismissed the lawsuit without prejudice.
 
 
AstraZeneca notes, thought, that "Notwithstanding the court's decision, the companycontinues to believe strongly in the merits of its position and is evaluatingits options."
 
The litigation was, essentially, a
last-ditch effort by AstraZeneca to fend off generic competition forits top-selling antipsychotic drug Seroquel (quetiapine) and to "vigorouslydefend its legal rights" to a product that generated  $5.83 billion for itlast year. The goal of the litigation, which many analysts called a long shot, was to maintain market exclusivity until December.   
 
Specifically, the lawsuit sought to overturn the FDA's denialon March 7, 2012 of the company's Citizen Petitions with regard to Seroqueltablets and Seroquel XR extended release tablets. In the Citizen Petitions,AstraZeneca raised what it said were "important issues regarding labelingrequirements for generic copies of innovative medicines, as well as dataexclusivity rights granted to innovative companies that conduct new clinicaltrials."  
 
 
On Sept. 9, 2011, AstraZeneca had filed the Citizen Petitionwith the FDA for both Seroquel products, requesting the FDA withhold finalapproval of any generic quetiapine product that omits from its labeling certainwarning language that FDA required AstraZeneca to include in the labeling for Seroquel.At issue—and providing the hook for this lawsuit now—is that the FDA had ruledfinally this March that generic copies of the antidepressant drug would nothave to carry the same warnings about possible side effects—such as suicidalthoughts and high blood sugar levels--that the FDA has required AstraZeneca toput on the branded product.  
 
AstraZeneca said it was seeking an injunction "barring the FDAfrom granting final marketing approval of generic quetiapine until Dec. 2,2012, when regulatory exclusivity expires on important clinical trial data, or,alternatively, at least until a federal court has a meaningful opportunity toreview imminent FDA action regarding the pending generic marketingapplications."  
 
 
Generic copies of the original instant-release form ofSeroquel had been due to hit the U.S. market on March 26.   

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
A starry night sky reflected over calm water, symbolizing the discovery of hidden patterns in complex systems.

Technology Guide: Spatial biology techniques

Discover essential strategies and expert insights to navigate the expanding world of spatial biology.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue